AstraZeneca stock. Focus stays on the drugmaker's global pipeline.

AstraZeneca PLC (US6549022043) is a global biopharmaceutical company with a dual investor base and a long-running emphasis on oncology, cardiovascular, renal and metabolic, respiratory and immunology medicines.

Business model

The company sells prescription medicines across major therapeutic areas and relies on both in-market products and late-stage pipeline programs to drive revenue over time. Its investor relations site and corporate profile present AstraZeneca as a large-cap drugmaker with global operations and a U.S. market presence through American depositary shares.

Market context

For U.S. investors, AstraZeneca's trading structure and coverage matter as much as the science. The shares are followed alongside other large healthcare names, and the business is exposed to U.S. pricing, reimbursement and trial-readout headlines that can move sentiment across the sector.

Representative product

One of the company's best-known products is Tagrisso, a lung-cancer medicine that illustrates the commercial reach of AstraZeneca's oncology portfolio. More broadly, the company uses flagship therapies and new launches to balance mature revenue streams with pipeline growth.

Stock context

AstraZeneca's U.S.-listed shares provide investors with a familiar entry point into a multinational drugmaker whose key drivers remain clinical data, regulatory updates and product execution. As of July 9, 2026, the shares trade in U.S. dollar terms on the company's American listing structure.